Inventurus Knowledge Solutions (IKS Health) has entered into a definitive agreement to acquire TruBridge, Inc., a fully integrated RCM and EHR vendor serving rural and mid-sized hospitals. The $557 million enterprise value transaction aims to combine IKS Health’s care enablement platform with TruBridge’s clinical and financial infrastructure. Expected to be PAT and EPS accretive in FY27, the deal significantly expands the company’s addressable market and accelerates its AI-first healthcare strategy.
Transaction Overview
IKS Health will acquire 100% of TruBridge, Inc. in an all-cash deal, effectively taking the US-listed entity private. The transaction is valued at an enterprise value of $557 million, funded by $600 million in secured debt. The acquisition is expected to close in Q2 FY 2027, following necessary regulatory and shareholder approvals. This deal is designed to be accretive to the company’s earnings from the first full fiscal year following integration.
Strategic Rationale and Market Synergy
The acquisition of TruBridge brings critical assets into the IKS Health portfolio, including a SaaS EHR platform and extensive revenue cycle management (RCM) capabilities. TruBridge serves approximately 1,500 clients with acute-care facilities under 400 beds. By integrating these services with IKS Health’s Agentic AI-powered Care Enablement Platform, the company expects to eliminate middleware friction, enhance data accuracy, and create a $575 million+ cross-sell opportunity within the existing client base.
Future Growth and Value Creation
IKS Health intends to leverage this merger to drive long-term value through its AI-first strategy. The integration is expected to yield significant efficiencies, including G&A optimization and advanced delivery transformation. Financially, the deal is supported by strong growth metrics from TruBridge, which reported 6% CAGR in revenue and 10% CAGR in adjusted EBITDA between 2020 and 2025. Looking ahead, IKS Health has set a vision for FY 2030 to reach an EBITDA of ₹3,000 crores, maintaining a stable net debt profile.
Integration Roadmap
The company has outlined a clear path for integration post-closing. Following a 90-120 day pre-close period where both entities will operate independently, the companies will undergo a 4-5 quarter integration phase. This will focus on unifying organizational structures, leadership, and commercial go-to-market strategies to fully realize the potential of the combined clinical and financial ecosystem.
Source: BSE
